학술논문
Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
Document Type
article
Author
Xia, Yue Yin; Gronwald, Jacek; Karlan, Beth; Lubinski, Jan; McCuaig, Jeanna M; Brooks, Jennifer; Moller, Pal; Eisen, Andrea; Sun, Sophie; Senter, Leigha; Bordeleau, Louise; Neuhausen, Susan L; Singer, Christian F; Tung, Nadine; Foulkes, William D; Sun, Ping; Narod, Steven A; Kotsopoulos, Joanne; Yerushalmi, Rinat; Fruscio, Robert; Rastelli, Antonella; Zovato, Stefania; Hyder, Zerin; Huzarski, Tomasz; Cybulski, Cezary; Sweet, Kevin; Wood, Marie; McKinnon, Wendy; Elser, Christine; Pal, Tuya; Wiesner, Georgia; Friedman, Eitan; Meschino, Wendy; Snyder, Carrie; Metcalfe, Kelly; Poll, Aletta; Gojska, Nicole; Warner, Ellen; Kim, Raymond H; Rosen, Barry; Demsky, Rochelle; Ainsworth, Peter; Panabaker, Karen; Steele, Linda; Saal, Howard; Serfas, Kim; Panchal, Seema; Cullinane, Carey A; Reilly, Robert E; Blum, Joanne L; Kwong, Ava; Rayson, Daniel; Isaacs, Claudine; Ramón y Cajal, Teresa; Dungan, Jeffrey; Cohen, Stephanie
Source
Gynecologic Oncology. 164(3)
Subject
Language
Abstract
Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women with BRCA mutations. Methods A total of 1733 matched pairs were included in this analysis. Women were matched according to year of birth, date of study entry, country of residence, BRCA mutation type and history of breast cancer. Detailed information on hormonal, reproductive and lifestyle exposures were collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with each contraceptive exposure. Results Ever use of any contraceptive was significantly associated with reduced risk of ovarian cancer (OR = 0.62; 95% CI 0.52-0.75; P